Compare KULR & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KULR | TLSA |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 155.3M |
| IPO Year | 2016 | 2017 |
| Metric | KULR | TLSA |
|---|---|---|
| Price | $3.83 | $1.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 264.3K |
| Earning Date | 05-15-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,274,028.00 | N/A |
| Revenue This Year | $123.93 | N/A |
| Revenue Next Year | $63.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.08 |
| 52 Week High | $7.49 | $2.60 |
| Indicator | KULR | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 49.97 | 32.88 |
| Support Level | $3.03 | N/A |
| Resistance Level | $4.47 | $1.61 |
| Average True Range (ATR) | 0.51 | 0.12 |
| MACD | -0.15 | -0.04 |
| Stochastic Oscillator | 18.25 | 9.26 |
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices. The Company operated two segments -EMP and Mining of Digital Assets.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.